1.

Both Tamoxifen and Aromatase inhibitor can be associated with risk of thromboembolism. Current NICE guideline (2018) does not provide any guidance about stopping endocrine therapy before elective breast surgery. This survey will help in assessing current practice in UK for discontinuing endocrine therapy prior to elective breast surgery for prevention of thromboembolism. We would be grateful to you for completing this short (4 min) survey. Your responses would remain anonymous.

Yours sincerely,
Pasupathy Kiruparan, Trust Consultant General and Breast Surgeon (mr.kiri@nhs.net) and
Debasish Debnath, Consultant Breast Surgeon (d.debnath@nhs.net)
Blackpool Victoria Hospital, Blackpool, FY3 8NR
01252-953813

Question Title

* 1. Are you a?

Question Title

* 2. Do you work mostly in a?

Question Title

* 3. Prior to elective surgery do you stop endocrine therapy, if it was indicated for?

Question Title

* 4. Prior to elective surgery do you stop endocrine therapy?

Question Title

* 5. How long before surgery do you stop endocrine therapy?

  Tamoxifen Aromatase inhibitor
Never
1 week
2 weeks
3 weeks
4 weeks
More than 4 weeks before surgery (please specify below)

Question Title

* 6. Do you stop endocrine therapy in?

  Tamoxifen Aromatase inhibitor
Not applicable (never stop endocrine therapy)
Short cases (< 60 min) only
Long cases (> 60 min) only
All cases

Question Title

* 7. Do you use pharmacological prophylaxis?

  Tamoxifen
(before surgery)
Tamoxifen
(after surgery)
Aromatase inhibitor  
(before surgery)
Aromatase inhibitor   
(after surgery)
Never
For 1 week
For 2 weeks
For 3 weeks
For 4 weeks
More than 4 weeks (please specify below)

Question Title

* 8. Type of pharmacological prophylaxis used

Question Title

* 9. When do you restart endocrine therapy after surgery?

  Tamoxifen Aromatase inhibitor
Not applicable (never stop endocrine therapy)
Next day after surgery
After 1 week
After 2 weeks
After 3 weeks
After 4 weeks
More than 4 weeks after surgery (please specify below)

Question Title

* 10. (Optional) Comments: Please provide any additional information (and/ or your email, if you would like to be informed about the outcome of the survey). Thank you for completing the survey.

0 of 10 answered
 

T